Department of Clinical Genetics, Odense University Hospital, 5000, Odense C, Denmark.
Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, 5000, Odense C, Denmark.
Sci Rep. 2020 Feb 7;10(1):2114. doi: 10.1038/s41598-020-58845-3.
Unexplained or idiopathic ketotic hypoglycemia (KH) is the most common type of hypoglycemia in children. The diagnosis is based on the exclusion of routine hormonal and metabolic causes of hypoglycemia. We aimed to identify novel genes that cause KH, as this may lead to a more targeted treatment. Deep phenotyping of ten preschool age at onset KH patients (boys, n = 5; girls, n = 5) was performed followed by trio exome sequencing and comprehensive bioinformatics analysis. Data analysis revealed four novel candidate genes: (1) NCOR1 in a patient with KH, iron deficiency and loose stools; (2) IGF2BP1 in a proband with KH, short stature and delayed bone age; (3) SLC5A2 in a proband with KH, intermittent glucosuria and extremely elevated p-GLP-1; and (4) NEK11 in a proband with ketotic hypoglycemia and liver affliction. These genes are associated with different metabolic processes, such as gluconeogenesis, translational regulation, and glucose transport. In conclusion, WES identified DNA variants in four different genes as potential novel causes of IKH, suggesting that IKH is a heterogeneous disorder that can be split into several novel diseases: NCOR1-KH, IGF2BP1-KH, SGLT2-KH or familial renal glucosuria KH, and NEK11-KH. Precision medicine treatment based on exome sequencing may lead to advances in the management of IKH.
不明原因或特发性酮症性低血糖(KH)是儿童最常见的低血糖类型。该诊断基于排除低血糖的常规激素和代谢原因。我们旨在确定导致 KH 的新基因,因为这可能导致更有针对性的治疗。对 10 名学龄前发病 KH 患者(男孩,n=5;女孩,n=5)进行了深度表型分析,然后进行了 trio 外显子组测序和综合生物信息学分析。数据分析显示了四个新的候选基因:(1)NCOR1 在患有 KH、缺铁和稀便的患者中;(2)IGF2BP1 在患有 KH、身材矮小和骨龄延迟的先证者中;(3)SLC5A2 在患有 KH、间歇性糖尿和极高 p-GLP-1 的先证者中;(4)NEK11 在患有酮症性低血糖和肝脏疾病的先证者中。这些基因与不同的代谢过程有关,如糖异生、翻译调节和葡萄糖转运。总之,WES 确定了四个不同基因中的 DNA 变异作为 IKH 的潜在新原因,表明 IKH 是一种异质性疾病,可以分为几种新疾病:NCOR1-KH、IGF2BP1-KH、SGLT2-KH 或家族性肾性糖尿 KH 和 NEK11-KH。基于外显子组测序的精准医学治疗可能会推动 IKH 管理的进展。